Here is some additional evidence that the approved label for DCVax-L in the US, UK, Canada, Germany and the rest of the EU, will not only include nGBM and rGBM, but will also include all high grade gliomas (Grade III and Grade IV gliomas). This will more than double the initial addressable market size for DCVax-L.
Take a look at the MHRA approved Paediatric Investigation Plan (PIP) for DCVax-L. As we all know, the PIP label will also closely mirror the approved label for adults treated with DCVax-L.
The conditions that are being treated in the PIP are not just nGBM and rGBM (Grade IV gliomas), but all high grade gliomas, which would also include Grade III gliomas:
News 
Market Data 
Discover 
AI
